Showing Results for
- Academic Journals (4,146)
Search Results
- 4,146
Academic Journals
- 4,146
-
From:MedSurg Nursing (Vol. 16, Issue 5) Peer-ReviewedChronic incurable pulmonary infections are the greatest threat to well-being and longevity for adults with cystic fibrosis (CF). Aggressive antibiotic therapy is required for infectious exacerbations. Knowledge of...
-
From:Science (Vol. 286, Issue 5444) Peer-ReviewedCystic fibrosis (CF) patients develop chronic airway infections with Pseudomonas aeruginosa (PA). Pseudomonas aeruginosa synthesized lipopolysaccharide (LPS) with a variety of penta- and hexa-acylated lipid A structures...
-
From:Expert Review of Anti-infective Therapy (Vol. 9, Issue 11) Peer-ReviewedAuthor(s): Baroukh Maurice Assael 1 Keywords : aerosol; aztreonam; cystic fibrosis; inhaled antibiotics; Pseudomonas aeruginosa Aztreonam inhalation solution (AZLI), a lyophilized form of the monobactam...
-
From:Annals of Thoracic Medicine (Vol. 4, Issue 3) Peer-ReviewedByline: Iara. Sequeiros, Nabil. Jarad There is a worldwide drive for the home management of chronic respiratory diseases. With the widespread use of home intravenous (IV) treatment for cystic fibrosis (CF) pulmonary...
-
From:Diabetes Care (Vol. 33, Issue 12) Peer-ReviewedCystic fibrosis (CF) is one of the most common life-threatening inherited disorders in Caucasian populations, affecting ~30,000 children and adults in the U.S. and 70,000 worldwide. Due to advances in pulmonary care and...
-
From:Family Practice News (Vol. 38, Issue 9)A drug for fixing a crucial defective protein in cystic fibrosis improved patients' lung function and sweat chloride levels, according to early results from a small randomized study. The investigational oral drug,...
-
From:JAAPA-Journal of the American Academy of Physicians Assistants (Vol. 26, Issue 2) Peer-ReviewedWhile many children have simplified the name of their disease to 65 roses, cystic fibrosis (CF) is not at all simple to manage. (1) The pulmonary component of CF is responsible for the associated mortality and predicted...
-
From:PLoS ONE (Vol. 11, Issue 9) Peer-ReviewedTGF-[beta]-induced endothelial-to-mesenchymal transition (EndoMT) is a newly recognized source of profibrotic activated myofibroblasts and has been suggested to play a role in the pathogenesis of various fibrotic...
-
From:Emerging Infectious Diseases (Vol. 8, Issue 7) Peer-ReviewedThe frequency of respiratory tract infections caused by Ralstonia species in persons with cystic fibrosis (CF) and the role of these species in CF pulmonary disease are not well documented. In part, this lack of...
-
From:PLoS ONE (Vol. 15, Issue 2) Peer-ReviewedBackground Pulmonary artery (PA) enlargement, defined as pulmonary artery to ascending aorta diameter ratio (PA:A)>1 on computed tomography (CT), is a marker of pulmonary vascular disease in chronic lung diseases. PA...
-
From:Italian Journal of Pediatrics (Vol. 41, Issue 1) Peer-ReviewedBackground Several factors can interfere with the full physical and emotional growth of adolescents, among them chronic diseases. The aim was to determine the nutritional status of adolescents and to associate it...
-
From:MPR Pharmacists' Edition (Vol. 6, Issue 1)Kalydeco (ivacaftor tablets; Vertex) has been approved to treat cystic fibrosis in patients [greater than or equal to] 6 years who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane...
-
From:The Oral History Review (Vol. 32, Issue 1) Peer-ReviewedAbstract The first sizeable cohort of people living with cystic fibrosis (CF) has now reached adulthood. Gradual improvements in the diagnosis and treatment of the disease have increased life expectancy to approximately...
-
From:Stem Cell Research & Therapy (Vol. 3, Issue 3) Peer-ReviewedIntroduction In lung fibrosis, alveolar epithelium degenerates progressively. The goal of regenerative medicine is to aid repair and regeneration of the lost tissues in parenchyma and airways for which mobilization...
-
From:Consultant (Vol. 38, Issue 9) Peer-ReviewedThe Cystic Fibrosis Foundation has organized a consensus conference where guidelines for accurately diagnosing the disease were laid out. Recommended strategies include diagnostic tests such as sweat tests, mutation...
-
From:Science (Vol. 288, Issue 5472) Peer-ReviewedChafing at the slow pace of commercial drug development, a disease advocacy group set out last week to finance new medicines for its constituency. On 31 May, the Cystic Fibrosis (CF) Foundation of Bethesda, Maryland,...
-
From:Chest (Vol. 127, Issue 3) Peer-ReviewedThe timing of the referral and listing of patients for lung transplantation remains a difficult decision. Life expectancy and quality of life with and without transplantation are the pivotal issues that need to be...
-
From:PLoS ONE (Vol. 10, Issue 2) Peer-ReviewedBackground Routine clinical diagnostics of CF patients focus only on a restricted set of well-known pathogenic species. Recent molecular studies suggest that infections could be polymicrobial with many bacteria not...
-
From:Personalized Medicine (Vol. 8, Issue 5) Peer-ReviewedAuthor(s): Melissa Ann Ashlock 1 KEYWORDS : ataluren; CFTR; cystic fibrosis; genotype; modulator; personalized medicine; potentiator; therapy; VX-770; VX-809 The field of personalized medicine, based on...
-
From:Journal of Clinical Investigation (Vol. 117, Issue 3) Peer-ReviewedFibroproliferative diseases, including the pulmonary fibroses, systemic sclerosis, liver cirrhosis, cardiovascular disease, progressive kidney disease, and macular degeneration, are a leading cause of morbidity and...